The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19. They have the ability to help the body fight a multitude of diseases, from ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

A revolutionary personalized cancer vaccine developed by Russia’s Gamaleya Research Institute of Epidemiology and ...

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking ...

Legislation that would block hospitals from transfusing blood containing COVID-19 antibodies or “synthetic mRNA” could have ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

While there is no evidence yet that H5N1 could spread between humans, pandemic preparedness is essential, and messenger ribonucleic acid (mRNA) vaccines offer great potential to mitigate a future ...

NASA's beleaguered Mars Sample Return program currently faces extreme costs of up to $11 billion and a timeline that could reach 2040. The year 2025 isn't even a week old and NASA is already ...

Both the U.S. and China are scripting strategies for bringing goodies back to Earth from Mars via their respective Mars Sample Return (MSR) endeavors. For America, things are currently happening ...

What about an mRNA vaccine for H5N1? There isn't one yet, but several companies—including Moderna, Pfizer and GlaxoSmithKline (in collaboration with CureVac)—are working on such a shot.

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...